Company rapidly prepares to submit IND and Breakthrough Therapy Status Applications DENVER, March 01, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced a positive meeting with the Food and Drug Administration (FDA)…


Previous articleField Trip Health and Cerebral Partner to Provide End-to-End Mental Health Care
Next articleThe Need for an International Psychedelic Religious Survey